Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Case report

Massive gastrointestinal bleeding in a patient with COVID-19

Mahmoud Mohamed, Mahmud Nassar, Nso Nso, Mostafa Alfishawy

Nephrology Department, University of Tennessee Health Science Center, Memphis, TN, USA
Medicine Department, Icahn School of Medicine at Mount Sinai/Queens, NY, USA
Infectious Disease Consultants and Academic Researchers of Egypt (IDCARE), Egypt

ABSTRACT

Despite the emerging data about the thrombophilic effect of the novel coronavirus [1], the relation between coagulation disorders and the COVID-19 pandemic is still not well understood. Various studies pointed to the significant role of the COVID-19 induced cytokine storm in development of the hypercoagulable state which leads to serious thromboembolic complications [2,3]. Some studies report the development of severe immune thrombocytopenia induced by the novel coronavirus [4]. Other studies found a correlation between COVID-19 disease and the development of disseminated intravascular coagulation (DIC) [5].

Patients with severe COVID-19 disease have an increased risk for development of gastrointestinal bleeding (GI) which may be related to stress [6], critical illness or mechanical ventilation [7]. Further studies showed the ability of the novel coronavirus to infect the epithelial cells of the GI tract [8]. Moreover, some data pointed to the ability of the virus even to infect the endothelium of blood vessels [9]. The relation between the COVID-19 pandemic and GI bleeding deserves more studies [10]. We present a case of GI bleeding in a patient with severe COVID-19 disease. We assume that COVID-19 disease can be a predominant factor for the development of DIC and GI bleeding.

Introduction

The prothrombotic outcomes of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have already been extensively reported [1]. However, the pathophysiology that may help elucidate the clinical correlation between coagulation disorders and the coronavirus disease 2019 (COVID-19) remains unclear. According to several clinical studies, COVID-19-induced cytokine storm might trigger hypercoagulable state and thromboembolic events [2,3]. The impact of COVID-19 on immune thrombocytopenia development is also emphasized [4]. In addition, a strong correlation is presumed to exist between COVID-19 and disseminated intravascular coagulation (DIC) [5].

Moreover, gastrointestinal (GI) bleeding in COVID-19 increases the risk of irreversible stress [6], critical illness, or mechanical ventilation [7]. COVID-19 might invade the epithelial cells of the GI tract [8]. Several clinical data highlighted the ability of COVID-19 to infect the endothelial cells [9]. However, current clinical studies have not unraveled the mechanisms responsible for inducing GI bleeding in patients with COVID-19 [10]. Here, we present a case of GI bleeding in a patient with severe COVID-19. Our findings will encourage the scientific community to validate the presumed clinical correlation between COVID-19 and DIC/GI bleeding.

Case presentation

A 75-year-old African-American male patient arrived in the emergency room with fever, cough, and nausea, preceded by malaise for 2 weeks. He had a past medical history of insulin-dependent diabetes, hypertension, and dyslipidemia. He received treatment for his symptoms and was discharged with a follow-up prescription. After 3 days, he re-developed shortness of breath, thereby readmitted for further treatment. Chest x-ray revealed interval worsening of bilateral, predominantly bibasilar, interstitial, and alveolar opacities.

Acute respiratory distress syndrome occurred; thus, supplemental oxygen therapy, intubation, and medical management were provided. The reverse transcription–polymerase chain reaction (RT-PCR) test revealed that he was positive for COVID-19. The medical management relied on azithromycin combined with hydroxychloroquine. However, acute renal failure developed in a few days; thus, he received heparin-free continuous renal replace-
ment therapy (CRRT). After 9 days, he was extubated. When his renal function markedly improved, he was transferred to the medicine floor.

Within a week of receiving CRRT, the patient developed hematochexia and became hemodynamically unstable. In the intensive care unit (ICU), he was assessed and diagnosed with hemorrhagic shock requiring massive blood transfusion, intubation (for airway protection), and inotropic support. Contrast-enhanced abdominal and pelvic computed tomography (CT) revealed bilobar airspace disease in scanned lung zones and a fat-containing ventral abdominal wall hernia with bowel loops. The diagnostic assessment excluded the possibility of incarceration and active GI bleeding. Thereafter, the patient underwent resuscitation in the ICU, followed by a repeat CT assessment, which ruled out the development of bleeding episodes.

Unfortunately, the bleeding reoccurred; hence, an intervention radiologist initiated a pelvic arteriography. The inferior mesenteric artery angiogram and superior rectal artery (SRA) angiography did not indicate any active contrast extravasation. The patient, however, underwent transscatheter gel foam embolization of the SRAs. Meanwhile, active contrast extravasation from the rectal branches was detected in the left hypogastric artery. A prostatic arteriogram confirmed the existence of contrast extravasation from the middle rectal artery; hence, gel-foam slurry arteriography was performed. These branches were embolized using gel foam pledges.

In conclusion, our findings support the claim that SARS-CoV-2 is a deleterious respiratory virus that discreetly disrupts the human body systems [18–21]. Thus, prospective studies aim to determine the effect of COVID-19 on various organ systems. Deepening our knowledge on COVID-19 is the key to curb the progression of COVID-19 worldwide.

In summary, our clinical report emphasizes on anticoagulant therapy to prevent and treat coagulopathy in COVID-19 scenarios [16,17]. The case-control study by Martin et al. (2020) reported a 60% prevalence of rectal tube-related rectal ulcers and an 80% prevalence of gastroduodenal ulcers in patients with COVID-19 [22]. They advocated conservative management to guide the treatment of fulminant DIC while disrupting the coagulation pathway [5]. The case-control study by Martin et al. (2020) reported a 60% prevalence of rectal tube-related rectal ulcers and an 80% prevalence of gastroduodenal ulcers in patients with COVID-19 [22]. They advocated conservative management to guide the treatment of fulminant DIC while disrupting the coagulation pathway [5]. The case-control study by Trindade et al. (2020) confirmed the mortality predisposition of patients with COVID-19 with GI bleeding during hospitalization [23].

SARS-CoV-2 is a deleterious respiratory virus that discreetly disrupts the human body systems [18–21]. Thus, prospective studies aim to determine the effect of COVID-19 on various organ systems. Deepening our knowledge on COVID-19 is the key to curb the progression of COVID-19 worldwide.

In conclusion, our findings support the claim that SARS-CoV-2 infection can trigger episodes of DIC and GI bleeding. Future studies should investigate the potential of COVID-19 to disrupt the structure and function of the coagulation pathways, blood vessels, and epithelial cells in the GI tract. These assessments will help identify new and comprehensive prevention and treatment approaches to improve the mortality rate and prognostic outcomes of COVID-19.

**Financial disclosure**

The authors declare the absence of funding for this study.

**Declaration of Competing Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References

[1] Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect 2020;9(1):687–90.

[2] Oudkerk M, Büller HR, Kuijpers D, van Es N, Oudkerk SF, McLoud T, et al. Diagnosis, prevention, and treatment of thromboembolic complications in COVID-19: Report of the National Institute for Public Health of the Netherlands. Radiology 2020;297(1):E216–22.

[3] Jose RJ, Manuel A. COVID-19 cytokine storm: The interplay between inflammation and coagulation. Lancet Respir Med 2020;8(6):e46–7.

[4] Magdi M, Rahil A. Severe immune thrombocytopenia complicated by intracerebral haemorrhage associated with coronavirus infection: A case report and literature review. Eur J Case Rep Intern Med 2019;6(7):001155.

[5] Lee, A. Y., COVID-19 and Coagulopathy: Frequently Asked Questions. https://www.hematology.org/covid-19/covid-19-and-coagulopathy2020, version 2.0.

[6] Plummer, M. P.; Blaser, A. R.; Deane, A. M., Stress ulceration: Prevalence, pathology and association with adverse outcomes. Crit Care; 2014, 18 (2), 213-213.

[7] Ali T, Harty RF. Stress-induced ulcer bleeding in critically ill patients. Gastroenterol Clin North Am 2009;38(2):245-65.

[8] Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med 2020;8(5):475–81.

[9] Brenda Goodman M. COVID-19 lung problems may start in blood vessels. Medscape 2020.

[10] Alborsaie M, Piscoya A, Tran QT, Mendelsohn RB, Butt AS, Lenz L, et al. “The Global Endo-COVID working group”. The global impact of COVID-19 on gastrointestinal endoscopy units: An international survey of endoscopists. Arab J Gastroenterol 2020;21(3):156-61.

[11] Gattinoni L, Chiurillo D, Rossi S. COVID-19 pneumonia: ARDS or not?. Crit Care 2020;24(1):154.

[12] Xu Z, Shi I, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8(4):420–2.

[13] Tian Y, Rong L, Nian W, He Y. Review article: Gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther 2020;51(9):843–51.

[14] Panagada M, Botrino N, Tagliabue P, Grasselli G, Novembri N, Panunzi S, et al. Hypercoagulability of COVID-19 patients in Intensive Care Unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 2020;18(7):1738–42.

[15] Spiezia L, Boscolo A, Poletro F, Cerruti I, Tiberio I, Campello E, et al. COVID-19-Related severe hypercoagulability in patients admitted to Intensive Care Unit for acute respiratory failure. Thromb Haemost 2020;120(6):998–1000.

[16] Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost 2020;18(7):1559–61.

[17] Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, Syvigos G. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action. Br J Haematol 2020;189(5):846–7.

[18] Ali H, Daoud A, Mohamed MM, Salim SA, Yessayan L, Baharani J, et al. Survival rate in acute kidney injury superimposed COVID-19 patients: A systematic review and meta-analysis. Ren Fail 2020;42(1):393–7.

[19] Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and multi-organ response. Curr Probl Cardiol 2020;45(8):100618. https://doi.org/10.1016/j.cpcardiol.2020.100618.

[20] Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, et al. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet 2020;395(10228):e52. https://doi.org/10.1016/S0140-6736(20)30558-4.

[21] Kassem AM. COVID-19: Mitigation or suppression?. Arab J Gastroenterol 2020;21(1):1–2.

[22] Martin TA, Wan DW, Hajifathalian K, Tewani S, Shah SL, Mehta A, et al. Gastrointestinal bleeding in patients with coronavirus disease 2019: A matched case-control study. Am J Gastroenterol 2020;115(10):1609–16. https://doi.org/10.1038/s41439-020-00608-5.

[23] Trindade AJ, Izard S, Coppa K, Hirsch JS, Lee C, Datapathy SK. Northwell, COVID-19_Research_Consortium. J Intern Med 2020;1–8. https://doi.org/10.1111/joim.13232.